- Home
- Publications
- Publication Search
- Publication Details
Title
Immunogenicity of TNF-Inhibitors
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 11, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2020-02-26
DOI
10.3389/fimmu.2020.00312
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- T Cell Response to Infliximab in Exposed Patients: A Longitudinal Analysis
- (2019) Sara Pratesi et al. Frontiers in Immunology
- Dynamics of circulating TNF during adalimumab treatment using a drug-tolerant TNF assay
- (2019) Lea C. Berkhout et al. Science Translational Medicine
- A single T cell epitope drives the neutralizing anti-drug antibody response to natalizumab in multiple sclerosis patients
- (2019) Antonino Cassotta et al. NATURE MEDICINE
- Comment on ‘Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial’ by Tanaka et al
- (2019) Lea C Berkhout et al. ANNALS OF THE RHEUMATIC DISEASES
- Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents
- (2019) Vibeke Strand et al. BIODRUGS
- The effect of methotrexate on tumour necrosis factor concentrations in etanercept-treated rheumatoid arthritis patients
- (2019) Lea C Berkhout et al. RHEUMATOLOGY
- Restricted immune activation and internalisation of anti-idiotype complexes between drug and antidrug antibodies
- (2018) Karin A van Schie et al. ANNALS OF THE RHEUMATIC DISEASES
- Review of immune tolerance induction in hemophilia A
- (2018) S.J. Schep et al. BLOOD REVIEWS
- Influence of Antigen Mass on the Pharmacokinetics of Therapeutic Antibodies in Humans
- (2018) David Ternant et al. CLINICAL PHARMACOKINETICS
- Identification of HLA-DRB1 association to adalimumab immunogenicity
- (2018) Mohan Liu et al. PLoS One
- Explaining Interpatient Variability in Adalimumab Pharmacokinetics in Patients With Crohnʼs Disease
- (2018) Sophie E. Berends et al. THERAPEUTIC DRUG MONITORING
- Defining the therapeutic range for adalimumab and predicting response in psoriasis: a multicenter prospective observational cohort study
- (2018) Nina Wilkinson et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis
- (2018) Jocelyn Quistrebert et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Neutralizing capacity of monoclonal and polyclonal anti-natalizumab antibodies: The immune response to antibody therapeutics preferentially targets the antigen-binding site
- (2017) Karin A. van Schie et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- IL-10–Producing Infliximab-Specific T Cells Regulate the Antidrug T Cell Response in Exposed Patients
- (2017) Alessandra Vultaggio et al. JOURNAL OF IMMUNOLOGY
- Serious infusion-related reaction after rituximab, abatacept and tocilizumab in rheumatoid arthritis: prospective registry data
- (2017) Jean-Hugues Salmon et al. RHEUMATOLOGY
- Immunogenicity of Therapeutic Antibodies
- (2017) Karien Bloem et al. THERAPEUTIC DRUG MONITORING
- The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study
- (2017) Robert J. Moots et al. PLoS One
- High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS cohort
- (2016) Meghna Jani et al. ANNALS OF THE RHEUMATIC DISEASES
- Circulating T cells to infliximab are detectable mainly in treated patients developing anti-drug antibodies and hypersensitivity reactions
- (2016) A. Vultaggio et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Potential Sources of Inter-Subject Variability in Monoclonal Antibody Pharmacokinetics
- (2016) Katherine L. Gill et al. CLINICAL PHARMACOKINETICS
- Higher Adalimumab Levels Are Associated with Histologic and Endoscopic Remission in Patients with Crohnʼs Disease and Ulcerative Colitis
- (2016) Andres J. Yarur et al. INFLAMMATORY BOWEL DISEASES
- Molecular Basis of Assembly and Activation of Complement Component C1 in Complex with Immunoglobulin G1 and Antigen
- (2016) Guanbo Wang et al. MOLECULAR CELL
- Serum tocilizumab trough concentration can be used to monitor systemic IL-6 receptor blockade in patients with rheumatoid arthritis: a prospective observational cohort study
- (2016) EL Kneepkens et al. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY
- Occurrence of Anti-Drug Antibodies against Interferon-Beta and Natalizumab in Multiple Sclerosis: A Collaborative Cohort Analysis
- (2016) Delphine Bachelet et al. PLoS One
- Comparative Immunogenicity of TNF Inhibitors: Impact on Clinical Efficacy and Tolerability in the Management of Autoimmune Diseases. A Systematic Review and Meta-Analysis
- (2015) Sarah S. Thomas et al. BIODRUGS
- Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis
- (2015) David Ternant et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Clinical Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies Approved to Treat Rheumatoid Arthritis
- (2015) David Ternant et al. CLINICAL PHARMACOKINETICS
- IgE antibodies and skin tests in immediate hypersensitivity reactions to infliximab in inflammatory bowel disease
- (2015) Estelle Fréling et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- US Guidelines for immune tolerance induction in patients with haemophilia a and inhibitors
- (2015) L. A. Valentino et al. HAEMOPHILIA
- Cross-reactive and pre-existing antibodies to therapeutic antibodies—Effects on treatment and immunogenicity
- (2015) Karin A van Schie et al. mAbs
- Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics
- (2015) Angela Schoch et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial
- (2014) Gerd-Rűdiger Burmester et al. ANNALS OF THE RHEUMATIC DISEASES
- Functional Analysis of the Anti-adalimumab Response Using Patient-derived Monoclonal Antibodies
- (2014) Pauline A. van Schouwenburg et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Complement Is Activated by IgG Hexamers Assembled at the Cell Surface
- (2014) C. A. Diebolder et al. SCIENCE
- Rituximab for treatment of inhibitors in haemophilia A
- (2014) Cindy Leissinger et al. THROMBOSIS AND HAEMOSTASIS
- Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient
- (2013) Niels Vande Casteele et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Key findings towards optimising adalimumab treatment: the concentration–effect curve
- (2013) Mieke F Pouw et al. ANNALS OF THE RHEUMATIC DISEASES
- Long-term measurement of anti-adalimumab using pH-shift-anti-idiotype antigen binding test shows predictive value and transient antibody formation
- (2013) Pauline A van Schouwenburg et al. ANNALS OF THE RHEUMATIC DISEASES
- Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single-centre, cohort study
- (2013) S.K. Mahil et al. BRITISH JOURNAL OF DERMATOLOGY
- Association Between Pharmacokinetics of Adalimumab and Mucosal Healing in Patients With Inflammatory Bowel Diseases
- (2013) Xavier Roblin et al. Clinical Gastroenterology and Hepatology
- Pharmacokinetics, Pharmacodynamics and Physiologically-Based Pharmacokinetic Modelling of Monoclonal Antibodies
- (2013) Miroslav Dostalek et al. CLINICAL PHARMACOKINETICS
- The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab
- (2013) Bella Ungar et al. GUT
- Antibodies to Infliximab and Risk of Infusion Reactions in Patients With Inflammatory Bowel Disease
- (2013) Sorcha O’Meara et al. INFLAMMATORY BOWEL DISEASES
- Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis
- (2013) Pauline A. van Schouwenburg et al. Nature Reviews Rheumatology
- Immunogenicity of Monoclonal Antibodies Against Tumor Necrosis Factor Used in Chronic Immune-Mediated Inflammatory Conditions
- (2013) Jose Ramon Maneiro et al. JAMA Internal Medicine
- Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner
- (2012) Charlotte L Krieckaert et al. ANNALS OF THE RHEUMATIC DISEASES
- Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation
- (2012) Pauline A van Schouwenburg et al. ANNALS OF THE RHEUMATIC DISEASES
- The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis
- (2012) Sandra Garcês et al. ANNALS OF THE RHEUMATIC DISEASES
- Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics-Based Dosing Paradigms
- (2012) I Ordás et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Immunogenicity of biological therapeutics
- (2012) Charlotte Krieckaert et al. CURRENT OPINION IN RHEUMATOLOGY
- Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease
- (2012) Casper Steenholdt et al. INFLAMMATORY BOWEL DISEASES
- IgG4 Production Against Adalimumab During Long Term Treatment of RA Patients
- (2012) Pauline A. van Schouwenburg et al. JOURNAL OF CLINICAL IMMUNOLOGY
- Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis
- (2012) Anke Vennegoor et al. Multiple Sclerosis Journal
- Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: A case series and cohort study
- (2011) L. A. Korswagen et al. ARTHRITIS AND RHEUMATISM
- The principal results of the International Immune Tolerance Study: a randomized dose comparison
- (2011) C. R. M. Hay et al. BLOOD
- Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis
- (2011) D. Pascual-Salcedo et al. RHEUMATOLOGY
- The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept
- (2010) A. Jamnitski et al. ANNALS OF THE RHEUMATIC DISEASES
- Population Pharmacokinetics of Therapeutic Monoclonal Antibodies
- (2010) Nathanael L. Dirks et al. CLINICAL PHARMACOKINETICS
- Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies
- (2010) Ron J. Keizer et al. CLINICAL PHARMACOKINETICS
- Dealing with immunogenicity of biologicals: assessment and clinical relevance
- (2010) Gerrit J Wolbink et al. CURRENT OPINION IN RHEUMATOLOGY
- Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions
- (2009) A. Vultaggio et al. ALLERGY
- Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study
- (2009) G. M. Bartelds et al. ANNALS OF THE RHEUMATIC DISEASES
- Anti-adalimumab antibodies in rheumatoid arthritis patients are associated with interleukin-10 gene polymorphisms
- (2009) G. M. Bartelds et al. ARTHRITIS AND RHEUMATISM
- Appearance of peripheral blood plasma cells and memory B cells in a primary and secondary immune response in humans
- (2009) G. Blanchard-Rohner et al. BLOOD
- HAHA – nothing to laugh about. Measuring the immunogenicity (human anti-human antibody response) induced by humanized monoclonal antibodies applying ELISA and SPR technology
- (2009) Andreas Nechansky JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
- Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis
- (2008) M K de Vries et al. ANNALS OF THE RHEUMATIC DISEASES
- Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes"
- (2008) A. S. De Groot et al. BLOOD
- Monoclonal Antibody Pharmacokinetics and Pharmacodynamics
- (2008) W Wang et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment
- (2008) Jinhai Wang et al. NATURE BIOTECHNOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started